| Literature DB >> 33976737 |
Chunmei Li1,2,3, Xiaoming Hou3, Shuqiao Yuan4, Yigan Zhang5, Wenzhen Yuan6, Xiaoguang Liu1,2,7, Juan Li1,2,8, Yuping Wang1,2, Quanlin Guan6, Yongning Zhou1,2.
Abstract
Background: To date, the pathogenesis of gastric cancer (GC) remains unclear. We combined public database resources and bioinformatics analysis methods, explored some novel genes and verified the experiments to further understand the pathogenesis of GC and to provide a promising target for anti-tumor therapy.Entities:
Keywords: EMT; PI3K/AKT pathway; TREM2; bioinformatics; gastric cancer (GC)
Year: 2021 PMID: 33976737 PMCID: PMC8100818 DOI: 10.7150/jca.55077
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1Identification of key genes and function and pathway analysis about GSE72305 and GSE103236. (A) The expression profile of gastric cancer related expressed genes. (B) Volcanic plot of gastric cancer-related differentially expressed genes (DEGs) respectively. (C, D) The biological process of EDGs by Gene Ontology (GO) and the biological pathways analysis of DEGs by Kyto Encyclopedia of Gene and Genomes (KEGG) enrichment about GSE72305 and GSE103236.
Figure 2Screening of hub genes by PPI network and model analysis. (A) Protein-protein interaction network of differentially expressed genes in GSE72305 and GSE103236. The different colored lines indicate the different evidences demonstrating the interaction. (B, C) The heatmap about expression profile of nine common genes in GSE72305 and GSE103236. (D) Seven common DEGs in GSE72305 and GSE103236 by Venn diagrm software.
Functional role of 16 hub genes
| Gene symbol | Full name | Function |
|---|---|---|
| BGN | biglycan | High expression of BGN enhance invasion and associated with a poor outcome in GC. |
| COL1A1 | collagen, type I, alpha 1 | High expression of COL1A1 promotes cell proliferation, migration, and invasion in GC. |
| COL4A1 | collagen, type IV, alpha 1 | COL4A1 may confer trastuzumab resistance and COL4A1 expression profiles can be reversed by drugs in GC. |
| COL5A2 | collagen, type V, alpha 2 | COL5A2 is a hub gene in most tumors, linked to angiogenesis, blood vessel development in MIBC. |
| NOX4 | NADPH oxidase 4 | NOX4 is involved in development and progression of GC, and as a new genetic target. |
| SPARC | secreted protein, acidic, cysteine-rich (osteonectin) | SPARC is associated with development and progression of GC, and predict GC recurrence. |
| HEYL | hes-related family bHLH transcription factor with YRPW motif-like | HEYL is target genes of Notch signaling pathway, involved in development and progression of most tumors. |
| SPP1 | secreted phosphoprotein 1 | High expression of SPP1 promoted proliferation, EMT process, but inhibited apoptosis of GC cells. |
| TIMP1 | TIMP metallopeptidase inhibitor 1 | High expression of TIMP1 is associated with proliferative potential and poor prognosis of GC. |
| CTHRC1 | Collagen triple helix repeat containing 1 | CTHRC1 is associated with invasion, metastasis and poor prognosis of GC. |
| TREM2 | Triggering receptor expressed on myeloid cells 2 | TREM2 have a role in chronic inflammations, related to poor prognosis of GC and progression of HCG, RCC, colon cancer. |
| SFRP4 | Secreted frizzled-related protein 4 | SFRP4 as modulators of Wnt signaling, and predicte chemotherapy response in resectable GC. |
| FBXO32 | F-box protein 32 | FBXO32 is a TGF-β/Smad signaling pathway target gene, can effected 5-FU resistance in GC. |
| GPX3 | Glutathione peroxidase 3 | GPX3 down-regulation in GC is due to aberrant promoter hypermethylation, suppressor of GC metastasis. |
| KIF4A | kinesin family member 4A | KIF4A is involved in development and progression of numerous types of cancer. |
| MMP9 | Matrix metalloproteinase 9 | High expression of MMP9 can promote metastasis in most tumors. |
GC: gastric cancer; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; MIBC: muscle-invasive bladder cancer.
Figure 3The survival analysis of the key genes in GC patients. The online Kaplan-Meier plotter tool was used to analysis the prognostic information of the 16 key genes. p<0.05 was considered statistically significant.
Figure 4The TREM2 expression level between GC sample and normal tissue with immunohistochemistry analysis from the human protein ATLAS.
Figure 5The expression of TREM2 in GC and affected cell proliferation. (A, B) TREM2 is high expression in GC cell lines at mRNA and protein levels. (C, D) Verified the ability of silence, shTREM2# 2 is more effectivity than shTREM2# 1 both in BGC-823 and SGC-7901 by RT-PCR and Western Blot. (E) The proliferation of BGC-823 and SGC-7901 were inhibited after knockdown of TREM2 measured by CCK8.
Relationship between the expression of TREM2 and clinical characteristics in GC patients
| Characteristic | No. tumors (%) | |||
|---|---|---|---|---|
| Total (n=393) | Low expression (n=192) | High expression (n=201) | ||
| 0.717 | ||||
| <60 | 118 | 56 (47.46) | 62 (52.54) | |
| ≥60 | 275 | 136 (49.45) | 139 (50.55) | |
| 0.764 | ||||
| Female | 138 | 66 (47.83) | 72 (52.17) | |
| Male | 255 | 126 (49.41) | 129 (50.59) | |
| 0.010* | ||||
| Tis and T1 | 19 | 15 (78.95) | 4 (21.05) | |
| T2 | 85 | 47 (55.29) | 38 (44.71) | |
| T3 | 185 | 88 (47.57) | 97 (52.43) | |
| T4 | 104 | 42 (40.38) | 62 (59.62) | |
| 0.817 | ||||
| N0 | 125 | 60 (48.00) | 65 (52.00) | |
| N1-3 | 268 | 132 (49.25) | 136 (50.75) | |
| 0.435 | ||||
| M0 | 372 | 180 (48.39) | 192 (51.61) | |
| M1 | 21 | 12 (57.14) | 9 (42.86) | |
| 0.014* | ||||
| Stage I | 53 | 35 (66.04) | 18 (33.96) | |
| Stage II | 135 | 58 (42.96) | 77 (57.04) | |
| Stage III | 172 | 79 (45.93) | 93 (54.07) | |
| Stage IV | 33 | 20 (60.61) | 13 (39.39) | |
| G1 | 11 | 5 (45.45) | 6 (54.55) | 0.000* |
| G2 | 143 | 94 (65.73) | 49 (34.27) | |
| G3 | 239 | 93 (38.91) | 146 (61.09) | |
| Diffuse | 71 | 27 (38.03) | 44 (61.97) | 0.015* |
| Intestinal | 183 | 103 (56.28) | 80 (43.72) | |
| NOS | 139 | 62 (44.60) | 77 (55.40) | |
| 0.006* | ||||
| Antrum | 145 | 70 (48.28) | 75 (51.72) | |
| Cardia | 51 | 25 (49.02) | 26 (50.98) | |
| Fundus | 141 | 59 (41.84) | 82 (58.16) | |
| GEJ | 48 | 35 (72.92) | 13 (27.08) | |
| NOS | 8 | 3 (37.50) | 5 (62.50) | |
*p<0.05, statistically.
Figure 6TREM2 affected the GC cell migration and invasion. Knockdown of TREM2, (A, B, C) the ability of migration assessed with wound healing assay and transwell migration assays (magnification, ×100), the ability of invasion measured by transwell invasion assays (magnification, X100). The statistical analysis was shown in the bar graphs (*, P<0.05, vs. control group; mean ± SD, n=3).
Figure 7TREM2 promote EMT by PI3K/AKT pathway. (A) In GC cell line SGC-7901, the expression of E-cadherin was increased after knockdown of TREM2, measured by immunofluorescence staining (magnification, X100). (B) After knockdown of TREM2, the expression of E-cadherin was increased, the expression of N-cadherin, Vimentin, p-PI3K, p-AKT were decreased, the expression of PI3K and AKT not changed significantly. (C) The statistical analysis of proteins expression was shown in the bar graphs (*, P<0.05, vs. control group; mean ± SD, n=3). (D) Protein interaction network of TREM2 interacts with PIK3R2, PIK3CA, and PIK3CB proteins predicted by string website.
Figure 8Knockdown of TREM2 inhibits GC cells metastasis in vivo. (A) The lung metastasis tumors about BGC-823 shCtrl group were increased than BGC-823 shTREM2# 2 group (n = 5/group). A representative photographs of gross lungs from indicated groups are shown (n = 5/group). (B) Representative H&E images of lung metastatic tumors.